# Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer

Source: https://onco.cc/trials/nct06507371/  
OnCo record `nct06507371` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Sir Run Run Shaw Hospital, active but no longer recruiting.

## Summary

Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer is a phase 3, randomised interventional study registered as NCT06507371 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 170 participants, started 2024-07-29 and due to reach its primary completion in 2026-05-04. Interventions recorded: node-sparing modified short-course radiotherapy; PD-1 antibody; Capecitabine; Oxaliplatin; standard short-course radiotherapy. Conditions listed: Rectal Cancer. Primary outcome: pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: "Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clinical stage is cT3-4bN0/+M0, and the lymph nodes are limited to the mesorectum". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: mRCAT-III
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06507371
- Phase: 3
- Setting: Node-sparing Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer : An Randomized, Prospective, Multicenter, Open-label, Phase III Clinical Trial (mRCAT-III)
- Sponsor: Sir Run Run Shaw Hospital
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT06507371: https://clinicaltrials.gov/study/NCT06507371

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06507371.json